Cargando…
Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281542/ https://www.ncbi.nlm.nih.gov/pubmed/32414207 http://dx.doi.org/10.3390/cancers12051224 |
_version_ | 1783543944782544896 |
---|---|
author | Sahi, Helka Their, Jenny Gissler, Mika Koljonen, Virve |
author_facet | Sahi, Helka Their, Jenny Gissler, Mika Koljonen, Virve |
author_sort | Sahi, Helka |
collection | PubMed |
description | Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986–2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the “early“ group with time of diagnosis between years 1986 and 2004 and the “late” group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation. |
format | Online Article Text |
id | pubmed-7281542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72815422020-06-17 Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study Sahi, Helka Their, Jenny Gissler, Mika Koljonen, Virve Cancers (Basel) Article Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986–2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the “early“ group with time of diagnosis between years 1986 and 2004 and the “late” group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation. MDPI 2020-05-13 /pmc/articles/PMC7281542/ /pubmed/32414207 http://dx.doi.org/10.3390/cancers12051224 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sahi, Helka Their, Jenny Gissler, Mika Koljonen, Virve Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title | Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title_full | Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title_fullStr | Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title_full_unstemmed | Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title_short | Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study |
title_sort | merkel cell carcinoma treatment in finland in 1986–2016—a real-world data study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281542/ https://www.ncbi.nlm.nih.gov/pubmed/32414207 http://dx.doi.org/10.3390/cancers12051224 |
work_keys_str_mv | AT sahihelka merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy AT theirjenny merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy AT gisslermika merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy AT koljonenvirve merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy |